Wegovy vs Mounjaro: The Complete UK Comparison Guide
Is Ozempic Wegovy? Understanding the Key Differences
The question "is Ozempic Wegovy" arises because both contain semaglutide, but they serve distinctly different medical purposes under UK licensing. Ozempic is exclusively licensed for managing type 2 diabetes, whilst Wegovy is specifically formulated and approved by the MHRA for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related health conditions. Promoting Wegovy for weight management constitutes illegal off-label advertising in the UK, making this distinction crucial for patients seeking legitimate treatment options.
When comparing Wegovy vs Mounjaro for weight management, you're looking at two different mechanisms of action entirely. Wegovy utilises semaglutide as a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which acts as a dual GIP and GLP-1 receptor agonist. This fundamental difference in how these prescription-only medicines work provides patients with distinct treatment pathways, each supported by comprehensive clinical trial data and NICE guidance.
Wegovy vs Mounjaro Pricing: Complete UK Cost Breakdown
EverydayMeds provides transparent pricing for both treatments, helping you understand the financial commitment involved. Wegovy follows a 5-dose escalation schedule: 0.25mg starter pens at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. Our bundle options, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, provide convenient multi-month supplies with Stock Available availability.
New customers benefit from code FIRST40, whilst returning patients use DOSE25, both applied automatically at checkout to reach these final prices. Both Wegovy and Mounjaro require the same rigorous clinical assessment process, with standard prescriber review taking 3 working days or express 24-hour options available. The choice between treatments should be based on clinical suitability rather than cost alone, as both represent significant investments in long-term weight management support.
Clinical Evidence: How Wegovy Performs vs Mounjaro Studies
When patients ask "is Ozempic Wegovy" in the context of effectiveness, they're often seeking weight loss data. The STEP trials for Wegovy demonstrated substantial results, with STEP 1 showing approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management alone.
Mounjaro's clinical programme presents its own compelling data set, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Both treatments require the same foundational approach of dietary modification and exercise enhancement, with the choice often depending on individual response patterns, tolerability profiles, and practical considerations such as dosing schedules and storage requirements.
How Wegovy Works: GLP-1 Mechanism Explained
Understanding "is Ozempic Wegovy" mechanistically helps clarify why Wegovy specifically targets weight management pathways. Semaglutide in Wegovy acts as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and food intake. This mechanism reduces hunger signals sent to the brain's appetite centres, promoting earlier satiety and reducing overall caloric consumption. The once-weekly FlexTouch pen delivers consistent medication levels, supporting sustained appetite regulation throughout the treatment period. Unlike Mounjaro's dual-pathway approach, Wegovy's focused GLP-1 action provides a well-established, extensively studied mechanism with predictable response patterns across diverse patient populations.
Ordering Process: From Assessment to Delivery
Both Wegovy and Mounjaro follow identical procurement processes through EverydayMeds' regulated pathway. The 3-minute online clinical assessment captures essential medical history, current medications, and weight management goals to ensure prescription safety. Our registered prescribers (operating under GPhC #9012878) review each application within standard 3 working days, with express 24-hour review available for urgent cases. Once approved, next-day delivery utilises specialised cold-chain transport maintaining the required 2-8°C temperature range throughout transit. This pharmaceutical-grade logistics ensure medication integrity from our registered pharmacy directly to your door, with discrete packaging and comprehensive storage instructions included.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements present a key practical difference when comparing these treatments. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for patients who travel frequently or lack consistent refrigeration access. The FlexTouch pen system used for Wegovy provides intuitive dose delivery with clear dose confirmation, whilst the mandatory dose escalation schedule (0.25mg through 2.4mg over 16 weeks) ensures optimal tolerability. Both treatments require careful handling and proper disposal of used pens through pharmacy take-back programmes.
Wegovy vs Mounjaro: Beyond Weight Loss Considerations
Patients asking "is Ozempic Wegovy vs Mounjaro" often focus solely on weight outcomes, but broader health implications matter equally. Wegovy's cardiovascular benefits, demonstrated in the SELECT trial, provide additional value for patients with existing heart disease risk factors. The established safety profile, with over 5 years of real-world use data, offers reassurance for long-term treatment planning.
Mounjaro's dual incretin pathway theoretically provides more comprehensive metabolic effects, though long-term cardiovascular outcome data remains limited compared to Wegovy's extensive evidence base. Both treatments address the chronic nature of obesity through sustained physiological changes rather than temporary appetite suppression, requiring ongoing commitment to dietary and lifestyle modifications for optimal results.
Making Your Choice: Both Available from EverydayMeds
Rather than determining which treatment is "better," focus on which aligns with your individual circumstances, medical history, and lifestyle preferences. EverydayMeds' unique position as a provider of both Wegovy and Mounjaro ensures unbiased clinical guidance based solely on your suitability for each treatment. Our prescribers consider factors including previous weight loss attempts, concurrent medications, travel requirements, and personal preferences when recommending between these prescription-only medicines. Begin your journey with confidence knowing both options remain available, with new customer pricing starting at £79.99 using code FIRST40, backed by our commitment to pharmaceutical excellence and patient support throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
